SCHEMBL4675183

SCHEMBL4675183

O=C(C=C(O)c1nc[nH]n1)c1[nH]ncc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.35
KCNH2 Q12809 4/20 0.35
CDK2 P24941 2/20 0.34
AKR1B1 P15121 1/20 0.34
IKBKB O14920 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP12 P39900 1/20 0.33
MMP13 P45452 1/20 0.33
MMP14 P50281 1/20 0.33
HTR2C P28335 1/20 0.32
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
NAMPT P43490 1/20 0.32
MAPT P10636 3/20 0.31
ALDH1A1 P00352 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
COMT P21964 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671593 0.89 AKR1B1 (0.34) AKR1B1NAMPTALDH1A1MEN1KMT2A
SCHEMBL4673902 0.84 CDK2 (0.33) HTR2AKCNH2CDK2AKR1B1IKBKB
SCHEMBL4672012 0.81 IKBKB (0.32) HTR2AKCNH2AKR1B1IKBKBMMP1
SCHEMBL4675515 0.81 COMT (0.32) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4671731 0.81 NPSR1 (0.41) AKR1B1IKBKBMMP1MMP2MMP3
SCHEMBL4673901 0.81 MAPT (0.32) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4670604 0.80 CDK2 (0.39) HTR2AKCNH2CDK2AKR1B1IKBKB
SCHEMBL4674048 0.80 AKR1B1 (0.41) HTR2AKCNH2AKR1B1NAMPT
SCHEMBL4672849 0.78 MAPT (0.34) CDK2MAPTALDH1A1L3MBTL1MEN1
SCHEMBL4671369 0.77 AKR1B1 (0.31) HTR2AKCNH2AKR1B1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HTR2A 441/4885KCNH2 3174/4885CDK2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.